Courtney W. Houchen

Oklahoma State University Oklahoma City — United States

Medicine · Health Sciences

55h-index8.8kcitations356works4.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Cells and Metastasis(78), Pancreatic and Hepatic Oncology Research(47), RNA modifications and cancer(37), Ferroptosis and cancer prognosis(27), Helicobacter pylori-related gastroenterology studies(23)

Publications355 total

Tumor-immune-neural circuit disrupts energy homeostasis in cancer cachexia
Cancer Cell·2026Open Access
Correction: MacCuaig et al. Toxicity Assessment of Mesoporous Silica Nanoparticles upon Intravenous Injection in Mice: Implications for Drug Delivery. Pharmaceutics 2022, 14, 969
Pharmaceutics·2026Open Access
Hepatocyte MLKL Drives Obesity-Driven Hepatocellular Carcinoma Progression via Mitochondrial Dysfunction Independent of Necroptosis in MASLD
2025Open Access
A novel D-peptide modulates DCLK1 gelsolin interactions, reducing PDAC tumor growth
Scientific Reports·2025Open Access
Tumor microenvironment and macroenvironment: A new perspective on holistic oncology
Cancer Letters·2025· 2 cited
Figure 2 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
2025Open Access
Supplementary Table S1 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
2025Open Access
Data from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
2025Open Access
Figure 3 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
2025Open Access
Supplementary Fig. S2 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
2025Open Access
Supplementary Fig. S5 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
2025Open Access
Supplementary Fig. S1 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
2025Open Access
Figure 4 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
2025Open Access
Supplementary Fig. S3 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
2025Open Access
Figure 1 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
2025Open Access
Supplementary Fig. S6 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
2025Open Access
Supplementary Fig. S4 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
2025Open Access
Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Cancer Research Communications·2025· 2 citedOpen Access
Corrigendum to “Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer” [Cancer Lett. 2023 Dec 1;578:216437]
Cancer Letters·2025
Balancing Regeneration and Resistance: Targeting DCLK1 to Mitigate Gastrointestinal Radiation Injury and Oncogenesis
Cancers·2025· 1 citedOpen Access
page 1 of 18Next →

Frequent Co-authors

Randal May(26), Sripathi M. Sureban(21), Shrikant Anant(21), Dongfeng Qu(13), Parthasarathy Chandrakesan(11), Nathaniel Weygant(11), Brian K. Dieckgraefe(9), Michael S. Bronze(9), Russell G. Postier(8), Naushad Ali(8), Stan Lightfoot(6), Rama P. Ramanujam(6), Jingxuan Yang(6), Satish Ramalingam(6), Mingyang Liu(5), Zhijun Zhou(5), Kar‐Ming Fung(5), Dharmalingam Subramaniam(5), Chinthalapally V. Rao(4), Lijun Xia(4)